Zydus Cadila gets USFDA nod to market impotence treatment drug

AHMEDABAD | MUMBAI | RAJKOT – In a press release submitted to the exchanges in India, Cadila Healthcare Ltd said of having got tentative approval to market drug to cure erectile dysfunction.

Zydus Cadila has received the tentative approval from the USFDA to market Vardenafil Hydrochloride Tablets (US RLD-Levitra) in the strengths of 2.5 mg, 5 mg, 10 mg and 20 mg, the company press release said.

The drug is an erectile dysfunction agent that works by blocking a certain enzyme (phosphodiesterase—PDES) used to treat erectile dysfunction (impotence), the release claimed.

It will be manufactured at the group’s formulations manufacturing facility at SEZ.

In line with this, the group now has 212 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

The group employs nearly 23,000 people worldwide and is dedicated to creating healthier communities globally.

Zydus aspires to be a research-based pharmaceutical company by 2020.

Announcement from the company cheered the investors & traders, resulting the company stock trading in GREEN Zone on positive counters, during the trading session on Indian Bourses on Monday.